Literature DB >> 19617833

Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency.

Deborah J Cook1, James Douketis, Donald Arnold, Mark A Crowther.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to critique and summarize clinical literature relevant to thromboprophylaxis in critically ill patients with renal insufficiency. The specific objectives are to discuss factors that increase the risks for bleeding and venous thromboembolism in critically ill patients, with a focus on patients with renal insufficiency, and to consider prophylaxis management options and the rationale for their use. RECENT
FINDINGS: Herein, we discuss both bleeding and venous thromboembolism in this population, both of which are of concern as complications. Bleeding is common among critically ill patients and has important clinical consequences. Critically ill patients with renal insufficiency require special consideration in regard to thromboprophylaxis. Such patients have a four-fold higher risk for developing venous thromboembolism compared with ICU patients without renal insufficiency. ICU patients have dynamic risks of thrombosis and bleeding. Invasive procedures may require temporary interruption of anticoagulants. Consequently, approaches to thromboprophylaxis require daily reevaluation.
SUMMARY: We provide some considerations for practice in the conclusion section.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19617833     DOI: 10.1097/MCP.0b013e32832ea4dd

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  3 in total

1.  Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective.

Authors:  Amisha M Parikh; Frederick A Spencer; Darleen Lessard; Catherine Emery; Ana Baylin; Crystal Linkletter; Robert J Goldberg
Journal:  Am J Kidney Dis       Date:  2011-08-27       Impact factor: 8.860

2.  A feasible strategy for preventing blood clots in critically ill patients with acute kidney injury (FBI): study protocol for a randomized controlled trial.

Authors:  Sian Robinson; Aleksander Zincuk; Ulla Lei Larsen; Claus Ekstrøm; Palle Toft
Journal:  Trials       Date:  2014-06-13       Impact factor: 2.279

3.  Tinzaparin Safety in Patients With Cancer and Renal Impairment: A Systematic Review.

Authors:  I A Vathiotis; N K Syrigos; E P Dimakakos
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.